Henan Taloph Pharmaceutical Stock Co. Ltd. Class A

Henan Taloph Pharmaceutical Stock Co. Ltd. Class A

SSSE:600222
6.15
CNY
-0.09
(-1.44%)
0.10EPS
85.72P/E
4.41BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.92
2.53
1.83
1.66
2.03
2.08
2.36
2.59
2.86
3.49
3.68
3.49
3.18
3.08
Basic EPS, GAAP
0.08
0.06
0.01
0.01
0.01
-0.2
0.08
0.05
0.01
-0.13
0.08
0.09
0.11
0.09
Free Cash Flow per Basic Share
-0.06
0.11
-0.02
0.02
-0.04
0.09
-0.12
- -
0.11
-0.34
- -
-0.14
0.05
- -
Dividend per Share
0.08
0.1
0.12
0.12
0.1
0.12
0.11
0.12
0.15
0.11
0.09
0.12
0.09
0.11
Book Value per Share
2.1
2.14
2.58
2.59
2.6
2.42
2.4
2.53
2.89
2.74
2.75
2.74
2.8
2.9
Tangible Book Value per Share
1.88
1.86
1.79
1.81
1.82
1.69
1.75
1.9
2.27
2.1
2.12
2.11
2.16
2.24
Basic Weighted Avg Shares
447
497
556
574
576
574
556
547
560
562
563
556
553
553
Sales/Revenue/Turnover
1,305
1,254
1,017
953
1,168
1,195
1,312
1,417
1,605
1,961
2,070
1,941
1,758
1,704
Operating Margin (%)
8.29
8.57
5.24
7.73
7.57
6.98
10.26
7.93
9.79
2.17
5.14
4.44
9.26
9.16
Depreciation Expense
40
43
49
53
51
51
38
41
57
63
68
65
64
- -
Net Income, GAAP
36
32
6
4
5
-115
44
29
6
-72
44
51
60
51
Effective Tax Rate (%)
22.82
23.02
- -
82.2
29.84
- -
10.04
5.62
9.01
- -
- -
- -
15.02
22.28
Profit Margin (%)
2.76
2.55
0.55
0.42
0.44
-9.65
3.39
2.06
0.37
-3.68
2.1
2.6
3.41
2.99
Working Capital
528
490
318
750
874
319
801
365
294
305
343
112
268
449
LT Debt
140
120
100
566
588
40
541
170
44
222
203
15
86
200
Total Equity
1,092
1,186
1,499
1,500
1,508
1,391
1,428
1,531
1,778
1,614
1,623
1,626
1,663
1,680
Return on Invested Capital (%)
3.5
2.76
- -
0.05
0.61
- -
1.78
1.15
1.12
- -
- -
- -
2.68
- -
Return on Capital (%)
3.95
2.98
- -
0.73
1.68
- -
4.03
3.72
2.75
- -
- -
- -
4.01
- -
Return on Common Equity (%)
4.32
3.04
0.44
0.27
0.34
-8.01
3.21
2.07
0.39
-4.47
2.77
3.2
3.77
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
721
728
826
LT Borrowings
222
197
180
LT Finance Leases
33
21
19
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
574
574
559
Market Capitalization
4,057
4,166
4,413

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,187
2,155
2,295
Cash, Cash Equivalents & STI
182
214
273
Accounts Receivable, Net
1,050
1,044
1,113
Inventories
463
471
439
Total Current Liabilities
1,737
1,708
1,845
Payables & Accruals
- -
- -
- -
ST Debt
721
728
826
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.26%
1.99%
2.23%
Free Cash Flow
-689.79%
-1,148.55%
-133.89%
Net Income, GAAP
-403.13%
-301.88%
18.74%
Sales/Revenue/Turnover
6.17%
5.07%
-9.46%
Total Cash Common Dividend
-0.62%
-1.11%
-26.5%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
499
428
413
601
1,941
2025
323
439
- -
571
1,758
2026
350
388
395
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.01
- -
0.04
0.09
2025
- -
0.03
- -
0.06
0.11
2026
- -
0.02
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.03
0.05
0.03
0.12
2025
0.03
0.02
- -
0.02
0.09
2026
0.04
0.02
0.03
- -
- -

Company Description

CEO
Jing Liang Li
Full Time Employees
2,084
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 8 Jinsuo Road Zhengzhou HN China 450001
IPO Date
Nov 5, 1999
Website
taloph.com
Business
Henan Taloph Pharmaceutical Stock Co., Ltd. Henan Taloph Pharmaceutical Stock Co., Ltd. (600222:CH) is a China-based company principally engaged in the research, development, manufacturing, and sale of pharmaceutical preparations and Chinese herbal medicines; its core products include Shuanghuanglian oral liquid series (concentrated and pediatric variants), Shuangjinlian mixture, Danshen oral liquid, pediatric heat-clearing and cough-relieving oral liquid, pediatric compound chicken gizzard chewable tablets, Huperzine A tablets, pediatric antipyretic oral solution, Shengmai drink, huziyanzong oral liquid, and compound yimu oral liquid, with exclusive offerings among Shuanghuanglian oral liquids, Shuangjinlian mixture, and pediatric compound chicken gizzard chewable tablets. The company operates four primary business segments encompassing pharmaceutical preparations, Chinese medicine tablets, drug research and development services including preclinical and clinical contract research through subsidiaries like Beijing New Leading Pharmaceutical Technology Development Co., Ltd., and pharmaceutical herbal medicine distribution via Henan Tongjuntang Daodi Medicinal Materials Co., Ltd.; it primarily serves hospitals, primary medical institutions, and retail terminals across domestic markets with headquarters in Zhengzhou, Henan Province, where it was founded in 1993 and listed on the Shanghai Stock Exchange in 1999 as the province's first pharmaceutical listing. Recent developments include approval for issuance of 800 million yuan in ultra-short-term financing bonds, changes to its subsidiary Tongjuntang Pharmaceutical Co., Ltd.'s legal representative, board, supervisory personnel, senior management, and business scope in 2025, full liquidation of the third phase of its employee stock ownership plan involving 10,846,100 shares, a 2024 production license change for Dew Drops Root Syrup, and a planned acquisition of stakes in two medicine firms for 516 million yuan announced in 2017, alongside recognition as a Key Leading Enterprise of Henan Province for Agricultural Industrialization in 2024.